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Abstract
Desmoid-type fibromatosis (DF) is a locally aggressive neoplasm characterized by muta-
tions in the CTNNB1 gene, which encodes the β-catenin protein. We reviewed 85 cases of
DF and performed Sanger sequencing for detecting mutations in CTNNB1 and immunos-
taining for detecting β-catenin localization. We included 70 DF samples, of which 56 cases
demonstrated nuclear β-catenin localization and 43 cases harboured CTNNB1 mutations.
CTNNB1-mutant DF samples consistently displayed nuclear β-catenin expression and were
derived from larger-sized tumours compared to samples with wild-type CTNNB1. When we
further classified DF cases into 2 subgroups based on the type of specimen, excised speci-
mens with nuclear β-catenin expression frequently displayed CTNNB1 mutation and no sta-
tistical correlation between nuclear β-catenin expression and CTNNB1 mutation was
observed in biopsies. When we classified CTNNB1 mutation cases into 2 subgroups (DF
with T41A or T41I, and DF with S45F or S45P), T41A or T41I mutations were observed
more frequently in males than in females. Additionally, DF tumours harbouring S45F or
S45P mutations were located more frequently in the abdominal wall than tumours with T41A
or T41I mutations. In conclusion, CTNNB1 mutation correlates with nuclear β-catenin
expression in larger or excised DF tumours, and DF harbouring CTNNB1 mutations mani-
fest variable clinical presentations.
Introduction
Desmoid-type fibromatosis (DF; also called desmoid tumour, deep fibromatosis, or aggressive
fibromatosis) is a borderline soft tissue tumour that displays variable aggressiveness and a high
proclivity for recurrence [1,2]. Because of the high recurrence rate and preventable morbidity
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associated with repeated surgeries, the treatment options for DF vary from surgery to watchful
waiting with careful follow-up [2–4]. DF tumours are classified based on their location as
tumours in the abdominal wall, intra-abdominal cavity, or extra-abdominal sites. It is well
known that up to 80% of sporadic lesions, regardless of tumour location, harbour mutations in
the CTNNB1 gene, which encodes the β-catenin protein [5]. The most common CTNNB1
mutations in DF are observed in exon 3 and include T41A, S45F, and S45P [1,6]. A novel path-
ogenic alteration in DF, the T41I mutation, was recently reported [7].
When mutations occur, β-catenin degradation is impaired in the cytoplasm, leading to its
accumulation in the nucleus [6,8–10]. Nuclear beta-catenin staining was seen in a very limited
subset of sof tissue tumor types, including desmoid-type fibromatosis, solitary fibrous tumor,
endometrial stromal sarcoma and synovial sarcoma [11]. β-catenin is expressed in approxi-
mately 70−75% of DF and is used to differentiate DF from postoperative scar formation caused
by other soft tissue tumours such as fibroblastoma [12]. Therefore, nuclear staining using an
antibody against β-catenin is used as a marker for diagnosing DF [6,13].
Smooth-muscle actin (SMA) is usually expressed in DF, but is an unspecific marker and is
not expressed in all cases of DF [12,14,15]. In diagnostic practice, it is hard to interpret subcel-
lular β-catenin expression in the biopsied specimens or in small-sized tissues because tumour
cells stain variably for β-catenin. Furthermore, genetic studies for identifying CTNNB1 muta-
tions cannot be performed for all specimens used for the diagnosis of DF in pathology labora-
tories. Further investigation is required to determine whether immunohistochemical staining
for β-catenin in different specimen types and in varying tumour sizes is indicative of mutations
in the CTNNB1 gene.
In this study, we reviewed 85 cases of pathologically diagnosed DF and performed β-catenin
immunohistochemical staining and CTNNB1 gene sequencing on tumour samples. Further-
more, we compared the β-catenin expression with CTNNB1 mutation status and analysed the




We retrospectively recruited 85 patients who were diagnosed with DF from 2005 to 2013 at
Severance Hospital, Yonsei University College of Medicine. Medical records were reviewed for
clinical features and radiological and pathological findings. To select the most representative
formalin-fixed paraffin-embedded (FFPE) tissues for immunohistochemical staining and
molecular studies, samples were mounted on slides, stained with haematoxylin and eosin, and
reviewed by two pathologists (JH Jung & SK Kim). The algorithm for the selection of eligible
cases of DF in this study is shown in Fig 1. We excluded the uninterpretable cases which did
not show internal positive control staining of β-catenin by immunohistochemistry. All the
uninterpretable cases had wild type CTNNB1 genes in Sanger sequencing. Finally, 70 speci-
mens of DF were included. Preoperative radiological imaging was available for 64 patients.
All methods and experimental protocols using human tissues were carried out in accor-
dance with relevant guidelines and regulations approved by the Institutional Review Board of
Severance Hospital, Yonsei University Health System, and the patients’ consent form were
waived (IRB no. 4-2016-0687).
Immunohistochemistry
FFPE blocks were cut into 4-μm-thick sections and processed using heat-induced epitope
retrieval. Immunohistochemical staining was performed in an automated immunostainer
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(Ventana Discovery1 XT, Ventana Medical System, Inc., Oro Valley, AZ, USA). Antibodies
against β-catenin (1:400, Cell Marque, #224ㅡ15) and SMA (1:1000, DAKO, #M0851) were uti-
lized. Two pathologists (JY Ahn & JH Jung) blinded to the pathologic information indepen-
dently evaluated the immunohistochemical staining. β-catenin staining was classified as
negative or positive according to the subcellular staining pattern. Cytoplasmic, membranous, or
Golgi staining pattern was regarded as negative expression and nuclear staining as positive
expression when observed in over 1% of tumour cells. We regarded positive expression for SMA
when it displayed cytoplasmic expression in more than 1% of the tumour area. We defined neg-
ative or positive staining regardless of staining intensity for both beta-catenin and SMA.
DNA extraction and sequencing
Polymerase chain reaction was conducted to evaluate CTNNB1 mutation status. Genomic
DNA was extracted from 10-μm sections cut from FFPE tissue blocks using the Maxwell1
CSC DNA FFPE extraction kit (Promega, Madison, WI, USA) and the Maxwell1 CSC instru-
ment. Polymerization was performed with the primers CTNNB1 ex3F (forward, 5’-TTTGA
TGGAGTTGGACATGG-3’) and ex3R (reverse, 5’-GAAGGACTGAGAAAATCCCTGTT-3’), to
amplify exon 3 of CTNNB1. The polymerization reaction was performed using Taq polymerase
(BIOLINE, London, UK), with 45 cycles of denaturation (94˚C, 30 sec), annealing (65˚C, 30
sec), and polymerization (72˚C, 30 sec). After purification by electrophoresis using a 2% aga-
rose gel containing ethidium bromide, analysis was conducted using the Pyromark Q24 2.0.7
Software.
Statistical analysis
All statistical analyses were performed using SPSS version 18.0 (IBM, Chicago, IL, USA) and
GraphPad Prism version 7.04 (GraphPad software, San Diego, CA, USA). The relationships
between groups were compared using the χ2 test, Fisher’s exact test, or unpaired t-test. Two-
sided P values < 0.05 were considered statistically significant.
Results
Clinical features of DFs
We reviewed 85 cases of pathologically diagnosed DF and performed immunohistochemical
staining for ß-catenin and CTNNB1 gene mutation tests on all the samples (Fig 1). Nuclear ß-
Fig 1. The algorithm for the selection of eligible cases of DF in this study. IHC, immunohistochemistry.
https://doi.org/10.1371/journal.pone.0250619.g001
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catenin expression was identified in 56 out of 85 DF samples, whereas CTNNB1 gene mutation
was observed in 43 out of 85 DF samples. Among the 85 cases of DF, we excluded 15 cases
which did not show internal positive control staining of β-catenin and these concurrently dis-
played negative ß-catenin staining and a wild-type CTNNB1 gene. Thus, we excluded these ß-
catenin-negative and CTNNB1-wild type cases for further analyses.
Next, we analysed clinicopathological features of 70 patients with DF (Table 1). All patients
were between 2 months and 84 years old (mean age: 36.01 ± 20.89 years) with 29 males and 41
females. Nine cases manifested in the abdominal wall (12.86%), 9 in the abdominal cavity
(12.86%), and 52 in extra-abdominal sites (74.29%). Tumour sizes were measured during pre-
operative imaging and ranged from 0.9 cm to 17.0 cm in size (mean size: 6.733 ± 4.424 cm).
Sixty tumours were excised and 10 cases were biopsied. Forty-three cases out of 60 patients
from whom tumours were excised underwent follow-up and 19 cases of recurrence were
observed (44.19%). We performed immunohistochemical staining for ß-catenin and SMA and
observed nuclear ß-catenin expression in 56 cases (80.0%; Fig 2) and SMA positivity in 61
cases (87.14%), which were found to be consistent with the literature [5]. There was no statisti-
cal difference between ß-catenin and SMA expressions in DFs (S1 Table).
CTNNB1 mutations in desmoid-type fibromatosis
Using Sanger sequencing, we detected CTNNB1 mutations in 43 out of 70 patients (61.43%;
Fig 2C). We divided DF patients into 2 groups according to ß-catenin expression and
CTNNB1 mutation status — those with ß-catenin expression or CTNNB1 mutations and those
without ß-catenin expression and CTNNB1 mutations — and compared clinical features
between the groups (S2 Table). There was no significant statistical difference in sex, age at
diagnosis, tumor site, tumor size, procedures, recurrence and SMA expression between the
groups.
Table 1. Clinicopathological parameters in desmoid-type fibromatosis patients.




Age (years; mean ± SD) 36.01 ± 20.89
Site
Abdominal wall 9 (12.9)
Abdominal cavity 9 (12.9)
Extra-abdominal sites 52 (74.3)











SD, standard deviation; SMA, smooth muscle actin.
https://doi.org/10.1371/journal.pone.0250619.t001
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Next, we divided DF patients into 2 groups — those with CTNNB1 mutations and those
without CTNNB1 mutations — and compared clinical features between the groups (Table 2).
The results demonstrated that DF cases harbouring CTNNB1 mutations were derived from
larger-sized tumours (7.655 ± 0.642 cm) compared with DF cases without CTNNB1 mutation
(4.973 ± 0.952 cm; p = 0.020). Immunostaining analysis found that ß-catenin nuclear expres-
sion was more frequent in DF cases harbouring CTNNB1 mutation (39/43, 90.70%) than in
DF cases without CTNNB1 mutation (17/27, 62.96%; p = 0.012). There were no significant dif-
ferences between the two groups with respect to gender, age at diagnosis, tumour site, speci-
men type or recurrence.
No statistical differences in ß-catenin expression (p = 0.674) and CTNNB1 mutation
(p = 0.493) were observed between biopsied tissues (n = 10, 14.29%) and excised tissues
(n = 60, 172 85.71%) (S3 Table). We further analysed the correlation between ß-catenin
expression and CTNNB1 mutation according to the specimen types (Table 3). Excised speci-
mens demonstrated nuclear ß-catenin expression more frequently in DF cases CTNNB1
mutated (34/38, 89.47%) than in CTNNB1 wild type tumours (13/22, 178 59.09%; p = 0.009).
On the contrary, there was no correlation between ß-catenin expression and CTNNB1 muta-
tion in the biopsy specimens (p> 0.999).
Clinicopathological features of desmoid-type fibromatosis according to
CTNNB1 mutation type
We detected CTNNB1 mutations in 43 out of 70 DF tumours (Table 4). Twenty-seven cases
displayed the T41A mutation (62.79%), 1 harboured the T41I mutation (2.33%), 12 cases
Fig 2. Immunohistochemical staining for β-catenin and identification of CTNNB1 gene mutation. A, Cytoplasmic
expression of β-catenin (negative). B, Nuclear expression of β-catenin (positive). C, CTNNB1 gene mutation in exon3
codon 41 (121A>G, T41A; 122C>T, T41I) and codon 45 (133T>C, S45P; 134C>T, S45F). Scale bar, 50μm.
https://doi.org/10.1371/journal.pone.0250619.g002
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Table 2. Clinicopathological findings in desmoid-type fibromatosis patients according to CTNNB1 mutation status.
CTNNB1 Wild-type (n = 27) CTNNB1 Mutation (n = 43) p-value
Sex 0.804
Male 12 (44.4) 17 (37.0)
Female 15 (55.6) 26 (63.0)
Age at diagnosis (years; mean ± SD) 31.93 ± 3.653 33.29 ± 5.642 0.099
Site 0.869
Abdominal wall 3 (11.1) 6 (14.0)
Abdominal cavity 3 (11.1) 6 (14.0)
Extra-abdominal 21 (77.8) 31 (72.1)
Size (cm; mean ± SD) 4.973 ± 0.952, n = 22 7.655 ± 0.642, n = 42 0.020
Specimen 0.493
Biopsy 5 (18.5) 5 (11.6)
Excision 22 (11.5) 38 (88.4)
Recurrence (n = 43) 0.349
Absent 10 (66.7) 14 (50.0)
Present 5 (33.3) 14 (50.0)
β-catenin expression 0.012
Negative 10 (37.0) 4 (9.3)
Positive 17 (63.0) 39 (90.7)
SMA expression 0.079
Negative 6 (22.2) 3 (7.0)
Positive 21 (77.8) 40 (93.0)
Values are expressed as n (%) unless otherwise specified. SD, standard deviation; SMA, smooth muscle actin.
https://doi.org/10.1371/journal.pone.0250619.t002
Table 3. β-catenin expression and CTNNB1 mutation status in desmoid-type fibromatosis patients according to specimen types.
Specimen type β-catenin expression CTNNB1 status, n (%) p-value
Wild-type Mutation
Total (n = 70) Negative 10 (37.0) 4 (9.0) 0.012
Positive 17 (63.0) 39 (91.0)
Excision (n = 60) Negative 9 (40.9) 4 (10.5) 0.009
Positive 13 (59.1) 34 (89.5)
Biopsy (n = 10) Negative 1 (20.0) 0 (0.0) >0.999
Positive 4 (80.0) 5 (100)
https://doi.org/10.1371/journal.pone.0250619.t003
Table 4. Mutation types of the CTNNB1 gene.







T41A & S45F 1 (2.33)
https://doi.org/10.1371/journal.pone.0250619.t004
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harboured the S45F mutation (27.91%), and 2 cases harboured the S45P mutation (4.64%).
One patient harboured both T41A and S45F mutations in the tumour.
After excluding the case of DF harbouring both T41A and S45F mutations, we divided the
remaining 42 DF patients with CTNNB1 mutation into two groups — those with the T41
mutation and those with the S45 mutation (Table 5). The T41 mutation occurred more fre-
quently in males (14/16, 87.50%) than in females (14/26, 83.85%; p = 0.042). The S45 mutation
occurred more frequently in the abdominal wall (5/14, 35.71%) than the T41 mutation (1/28,
3.57%; p = 0.008). However, there were no significant differences between the two groups with
respect to gender, age at diagnosis, tumour size, recurrence, and β-catenin or SMA expression.
Discussion
Mutations in the CTNNB1 gene, which encodes the β-catenin protein, is highly prevalent in
DF and is considered to contribute to tumour recurrence [16]. Using Sanger sequencing and
immunostaining, we detected a positive correlation between CTNNB1 gene mutation and
nuclear β-catenin expression in the DF specimens. It is known that up to 80% of sporadic DF
harbour mutations in the CTNNB1 gene [5]. However, we detected CTNNB1 mutations in 43
out of 70 patients (61.43%). We assume that the lower positive rate of DF with CTNNB1 muta-
tion is due to the limitation of biopsied tissues. We included 10 biopsied FFPE tissues in this
study, and we cannot exclude the possibility that the biopsied samples might not contain the
enough amount of tumor cells for sequencing. We believe that the positive rate of CTNNB1
mutation could increase if the research was carried out with more biopsied tissues.
We identified a patient harbouring both T41A and S45F mutations in his tumour. The
patient was a 48-year-old man with a 4.5-cm sized chest wall mass encasing the rib. Addition-
ally, we detected a T41I mutation in a DF patient, who was a 3-month-old boy with a
5 × 4.8-cm sized scalp mass. A recent study reported that three CTNNB1 T41I variants were
Table 5. Clinicopathological findings in desmoid-type fibromatosis patients according to CTNNB1 mutation types.
CTNNB1 Mutation Type T41A or T41I (n = 28) S45F or S45P (n = 14) p-value
Sex 0.042
Male 14 (50.0) 2 (14.3)
Female 14 (50.0) 12 (85.7)
Age (years; mean ± SD) 31.93 ± 3.653 33.29 ± 5.642 0.836
Site 0.008
Abdominal wall 1 (3.6) 5 (35.7)
Abdominal cavity 6 (21.4) 0 (0.0)
Extra-abdominal sites 21 (75.0) 9 (64.3)
Size (cm; mean ± SD) 7.675 ± 0.8431 7.854 ± 1.021 0.901
Recurrence 0.237
Absent 11 (61.1) 3 (30.0)
Present 7 (38.9) 7 (70.0)
β-catenin expression 0.100
Negative 1 (3.6) 3 (21.4)
Positive 27 (96.4) 11 (78.6)
SMA expression 0.545
Negative 2 (7.1) 0 (0.0)
Positive 26 (92.9) 14 (100.0)
Values are expressed as n (%) unless otherwise specified. SD, standard deviation; SMA, smooth muscle actin.
https://doi.org/10.1371/journal.pone.0250619.t005
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preferentially detected in paediatric DF patients (n = 3/22; 13.6%), with only a single instance
of DF in an adult (n = 1/170; 0.6%) [7].
Among the mutations, the S45F mutation is implicated as a factor that increases the rate of
tumour recurrence after excision [2,16–18]. In this study, we reviewed 43 out of 70 DF patients
with follow-up data from our institution. However, no significant differences in recurrence
were observed between the DF groups with or without CTNNB1 gene mutations. When we
investigated recurrences among DF patients with CTNNB1 gene mutations, there was no sta-
tistical difference between the two groups — DF with T41A or T41I mutation, and DF with
S45F or S45P.
We speculated that stabilization and subsequent nuclear localization of β-catenin could be
representative of CTNNB1 mutation status. Indeed, immunostaining results demonstrated
that nuclear β-catenin expression was observed more frequently in DF cases with CTNNB1
mutation than in DF cases without CTNNB1 mutation. We presented four cases with
CTNNB1 mutation which had beta-catenin expression with cytoplasmic/membranous/Golgi
staining pattern. The relationship between CTNNB1 gene mutation, β-catenin nuclear locali-
zation, and Wnt pathway activation is complex. According to the literatures, nearly half of
CTNNB1 mutant cases of endometrial carcinoma had only 5–10% of tumor cells with β-cate-
nin nuclear localization, and the authors suggested that immunohistochemistry could be an
initial screen, with CTNNB1 sequencing employed when nuclear localization of β-catenin is
absent [9]. Audard et al. report that 37% of tumors with β-catenin mutations they examined
were without cytosolic/nuclear staining of β-catenin in hepatocellular carcinoma [19]. Fur-
thermore, CTNNB1 mutation was observed more frequently in the larger-sized tumours.
Therefore, if the excised tumour is small in size, we need to know that β-catenin immunostain-
ing is indicative of the presence of CTNNB1 mutation, particularly in the case of recurrent
tumours. In this study, we divided DF cases into 2 groups according to the specimen types:
biopsied tissues and excised tissues. Notably, the correlation between nuclear localization of β-
catenin and CTNNB1 mutation was not identified in biopsied DF tissues. Therefore, we sug-
gest that the CTNNB1 mutation can be identified in a biopsied specimen even though β-cate-
nin expression is found in the cytoplasm or the membrane and vice versa.
In conclusion, we found that nuclear localization of β-catenin correlated with the CTNNB1
gene mutation status in DF, and DF demonstrated different clinicopathological features based
on the mutations they harbour. We newly identified a patient harbouring both T41A and S45F
mutations in his tumour. We demonstrated that CTNNB1 mutation correlates with nuclear β-
catenin expression in larger or excised DF tumours, therefore caution is advised in the inter-
pretation of the immunohistochemical and mutation data when derived from biopsied sam-
ples or small tumours.
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